{
  "id": 7176055,
  "title": "Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026",
  "url": "https://urgent.news/2026/09/13/definium-therapeutics-to-discuss-topline-results-from-phase-3",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-13T21:03:09.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/definium-therapeutics-to-discuss-topline-results-from-phase-3-panorama-study-in-generalized-anxiety-disorder-on-september-14-2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "Definium Therapeutics will host a live webcast on September 14, 2026, at 8 a.m. EDT to discuss topline results from its Panorama Phase 3 study. The study evaluated DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD).\n\nThe Panorama study, according to Investing.com, was a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 245 participants aged 18 to 74 years across approximately 32 study centers. Participants were randomized 2:1:2 to receive a single dose of DT120 ODT 100 µg, DT120 ODT 50 µg, or matching placebo.\n\nThe study consisted of a 12-week double-blind treatment period followed by a 40-week open-label extension. The primary endpoint was change from baseline in Hamilton Anxiety Rating Scale total score at Week 12.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Definium to present phase 3 anxiety disorder trial results Monday",
        "url": "https://urgent.news/2026/09/13/definium-to-present-phase-3-anxiety-disorder-trial-results-monday",
        "published": "2026-09-13T21:04:38.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}